Decreased neutrophil levels in HIF^C mice correlates to decreased production of CXCL1 and not migration defects. by Kelly M. Shepardson (404375)

Inhibition of NLRP3 inflammasomes decreased 5-FU-induced cell death. by Kaya Yoshida (658943)

An ATR-specific inhibitor decreases HBoV1 infection of HAE-ALI. by Xuefeng Deng (138723)

An ATM-specific inhibitor decreases HBoV1 infection of HAE-ALI. by Xuefeng Deng (138723)

Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G. by Régis Cohen (11419436)

Subjects:

Spatial training decreases the association between Ndfip1 and Nedd4 and decreases endogenous Beclin 1 ubiquitination in the hippocampus. by Wei-Lun Hsu (1756123)

“…Endogenous Beclin 1 ubiquitination level is decreased in Nedd4 siRNA-transfected rats (t_1,6 = 5.78, <i>p</i> = 0.001). …”

Botulinum toxin A (3.5 U/kg) decreases mechanical allodynia induced by IoNC- injury in rats. by Boris Filipović (336089)

A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization-5 by Chandrashekhar D Kamat (60176)

“…<p><b>Copyright information:</b></p><p>Taken from "A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization"</p><p>BMC Cardiovascular Disorders 2007;7():4-4.…”

SARS-CoV-2 decreases excitatory synapses, while influenza A does not induce cell death in BCO. by Pinar Mesci (14053895)

Absence of PML decreases the co-localization of DAXX and ATRX but not HIRA and UBN1 with latent/quiescent HSV-1 genomes. by Camille Cohen (2440810)

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: